Related Experiment Video
Updated: Mar 29, 2026
Chinese Herbal Retention Enema for the Treatment of Ulcerative Colitis
Published on: May 16, 2025
[Guideline for the Treatment of Ulcerative Colitis and Crohn's Disease in Adult Patients]
Paulina Núñez F1, Ignacio Alfaro2, Carolina Pavez3
1Centro de Enfermedades Digestivas, Clínica Universidad de los Andes, Universidad de los Andes, Santiago, Chile.
Insights
New clinical guidelines offer evidence-based treatment options for ulcerative colitis and Crohn's disease in Chile. These guidelines aim to improve inflammatory bowel disease (IBD) management and patient quality of life.
Area of Science:
- Gastroenterology and Internal Medicine
- Clinical Practice Guidelines
- Inflammatory Bowel Disease (IBD) Research
Background:
- Ulcerative colitis and Crohn's disease are severe chronic conditions impacting patient quality of life.
- Limited epidemiological data exists for inflammatory bowel disease (IBD) in Latin America, despite a significant disease burden.
- Challenges in diagnosis, advanced therapy access, and long-term management persist in the region.
Purpose of the Study:
- To provide Chilean physicians with clear, evidence-based information on therapeutic options for ulcerative colitis and Crohn's disease.
- To support shared decision-making between healthcare providers and patients for personalized IBD treatment plans.
- To optimize IBD management in Chile and promote equitable access to treatments.
Main Methods:
- Systematic review of the best available evidence on IBD treatments.
- Development of clinical guidelines by the Chilean Working Group on Crohn's Disease and Ulcerative Colitis (ACTECCU).
- Incorporation of clinical expertise from a national panel of IBD specialists.
Main Results:
- The guidelines present up-to-date information on the quality and strength of evidence for various therapeutic options.
- The document facilitates personalized treatment planning based on individual patient needs and characteristics.
- Focus on optimizing management and improving health outcomes for IBD patients in Chile.
Conclusions:
- These guidelines represent a crucial step in enhancing the comprehensive management of inflammatory bowel disease in Chile.
- Implementation aims to improve health outcomes and quality of life for patients with ulcerative colitis and Crohn's disease.
- Promotes evidence-based care and equitable access to advanced therapies within the Chilean healthcare system.
Abstract:
Ulcerative colitis and Crohn's disease are chronic conditions that can take a potentially severe or even life-threatening course, with high morbidity stemming from their complications. These diseases affect not only physical health but also significantly impact the quality of life of patients and their families. The primary goal of these guidelines is to provide treating physicians with clear, up-to-date information regarding the quality and strength of evidence supporting each therapeutic option. The document is intended to support shared clinical decision-making, empowering healthcare providers and patients to jointly develop a personalized treatment plan tailored to individual needs, preferences, and clinical characteristics. Although epidemio-logical data on inflammatory bowel disease (IBD) in Latin America remain limited, multiple studies have highlighted a substantial disease burden across the region, along with ongoing challenges in diagnosis, access to advanced therapies, and long-term management. In response to these needs -and recognizing the continuous advances in therapeutic strategies- the Chilean Working Group on Crohn's Disease and Ulcerative Colitis (ACTECCU) undertook the development of clinical guidelines aimed at the treatment of IBD in adult patients. The guideline was developed through a systematic review of the best available evidence, enriched by the active participation of a national panel of specialists who contributed their clinical expertise in the comprehensive management of IBD. Ultimately, these guidelines aim to optimize the management of IBD in Chile, promote more equitable access to evidence-based treatments, and improve health outcomes and quality of life for those living with these chronic conditions.
More Related Videos
08:58Analyzing Beneficial Effects of Nutritional Supplements on Intestinal Epithelial Barrier Functions During Experimental Colitis
Published on: January 5, 2017
05:41Therapeutic Evaluation of Fecal Microbiota Transplantation in an Interleukin 10-Deficient Mouse Model
Published on: April 6, 2022
Related Concept Videos
01:29Drugs for Treatment of Ulcerative Colitis in IBD
01:29Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
01:21Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
01:30Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
01:21Inflammatory Bowel Disease V: Surgical Management
Here are some common surgical interventions for IBD:
01:27Inflammatory Bowel Disease I: Ulcerative Colitis
Inflammatory bowel disease, or IBD, encompasses a group of disorders characterized by chronic inflammation or ulceration of the gastrointestinal tract.
Risk Factors
The exact cause of IBD remains unclear, although it is believed to be due to a mix of genetic, environmental, microbial, and immune factors. Genetic factors are significant in determining susceptibility to IBD, with family history being a critical risk factor. Individuals with a first-degree relative who has IBD are at...